Director Of Corporate Strategy

Job description:

We pride ourselves on our integrity. We do what’s right for our employees, patients, and partners, and so can you. 

 

We are currently recruiting for a Director, Corporate Strategy to work within its Strategy & Marketing function.

 

Reporting to the Vice President & Head of Strategy & Marketing, and located in either the UK, France, Germany or the US, the purpose of the roles is to oversee all strategy development activities of Oxford Biomedica including the supervision and alignment of market intelligence activities.

 

Your responsibilities in this role would be: 

 

 

• Oversight and coordination of all market intelligence activities that will form the foundation for the definition of the strategy.
• Devising and implementing an annual rolling strategy definition process with key performance indicators.
• Defining and aligning the growth (organic/inorganic) strategy of the OXB by aligning closely with other functions such as Operations, Commercial & R&D.
• Assessing the complexities of the business and market to support strategy initiation & definition.
• Lead relevant and transformational strategic projects across the different business segments of OXB
• Support M&A and PMI activities.
• Devise an implementation roadmap and the necessary governance.
• Lead communication with different stakeholders and facilitate change management.
• Preparing potential business models and assessing financial impact (e.g. define business cases). 

Profile description:

We are looking for:

 

• Advanced degree strongly preferred (PhD, MD, MBA) with scientific, engineering or business discipline a plus.
• Considerable experience in Life Science industry preferable in a service environment (e.g. CDMO, CRO, Testing).
• Strong understanding of the Pharma and/or Biotech industry.
• Demonstratable competency with strategy development either in a consulting or Corporate Strategy environment
• Working knowledge and influence within M&A feasibility environments (e.g. due-diligence, target identification, etc.)
• Proven experience delivering on Projects within a matrix organization ideally in Corporate Development with a high degree of flexibility.
• A strong communicator able to communicate, collaborate & influence across multiple levels.

 

 

About Us:

 

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

 

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

 

What’s in it for you:

 

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity
• State of the art laboratory and manufacturing facilities

 

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment, and teamwork, and so can you.

 

Collaborate. Contribute. Change lives.

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

 

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

 

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.